LXRX : Summary for Lexicon Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 12 mins

Lexicon Pharmaceuticals, Inc. (LXRX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.98+0.35 (+2.39%)
At close: 4:00 PM EST
People also watch:
ARRYFOLDCYTKDVAXPGNX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close14.63
Open0.00
Bid11.12 x 100
Ask19.98 x 100
Day's Range14.33 - 15.04
52 Week Range7.65 - 19.62
Volume619,189
Avg. Volume905,615
Market Cap1.56B
Beta-0.10
PE Ratio (TTM)-69.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?
    Insider Monkey3 days ago

    Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • PR Newswire14 days ago

    Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl

    THE WOODLANDS, Texas, Nov. 21, 2016 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), today announced the appointments of Alexander Santini as chief commercial officer, Kiernan Seth, Ph.D. as vice president of marketing, and Gary Branch as vice president of sales.  Mr. Santini will have responsibility for all commercial activities in the United States for telotristat ethyl, an investigational oral drug for the treatment of carcinoid syndrome, with Dr. Seth and Mr. Branch reporting directly to him. With over 30 years of varied health care experience, Mr. Santini has demonstrated the ability to build, lead and motivate cross functional teams responsible for driving successful product launches and customer service improvements, while building strategic partnerships with key decision makers.  Mr. Santini joined Lexicon in April 2015 and was previously responsible for developing the market access and channel management strategy for telotristat ethyl.  Prior to joining Lexicon, Mr. Santini served as executive member and vice president of market access for the Bayer U.S. Pharmaceutical organization where he had executive responsibility for market access, pricing, trade and channel management, and payer account management for the entire Bayer U.S. drug portfolio.  Prior to Bayer Pharmaceuticals, Mr. Santini held executive leadership roles of increasing responsibility at Berlex Laboratories.  Prior to embarking on his career in the pharmaceutical industry, Mr. Santini served as a non-commissioned officer in the U.S. Air Force, where he completed the Radiologic Technology Program at the U.S. Air Force School of Health Care Science and an AAS degree in Business Marketing from Westchester Community College in Valhalla, New York.  During his tour of duty Alex was awarded the Certificate of Appreciation from the U.S. Secretary of Defense for exemplary outstanding performance of duties in support of the 1980 XIII Olympic Winter Games, Lake Placid, New York.

  • Capital Cube19 days ago

    ETFs with exposure to Lexicon Pharmaceuticals, Inc. : November 16, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Lexicon Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to LXRX-US. Comparing the performance and risk of Lexicon Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)